ABTAbbott Laboratories
Price
-25%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growth steady, the market undecided.
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott’s* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market. The acquisition is subject to customary closing conditions, including the approval of Exact Sciences shareholders and obtaining the required regulatory clearances.
In the company’s own words · 10-K filed Feb 20, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Abbott Laboratories (ABT) reported revenue of $11.2B in Q1 2026 (quarter ended Mar 31, 2026), up 7.8% from the same quarter a year earlier. That came with a gross margin of 56% and net income of $1.08B (9.6% of revenue). For the full year FY2025, revenue was $44.3B (+5.7% year on year) and net income $6.52B. Its largest segment in Jun 2026 was Nutritional Products at $525M, 41% of the disclosed total, ahead of Diagnostic Products at 29%. The next results filing is expected around Oct 14, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 20, 2026As previously reported in Abbott’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, Abbott is a defendant in numerous lawsuits alleging that preterm infants developed necrotizing enterocolitis (“NEC”) as a result …Regulation FD disclosure · Form 8-K
- Jul 16, 2026Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance.Earnings release · press release
- Apr 27, 2026On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $1.28BThe company’s own SEC segment disclosure.
- Nutritional Products$525.0M41%
- Diagnostic Products$377.0M29%
- Medical Devices$377.0M29%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Devices
The closest names by size in the same industry